AnaptysBio's (NASDAQ:ANAB) Performance Is Even Better Than Its Earnings Suggest

By
Simply Wall St
Published
November 10, 2021
NasdaqGS:ANAB
Source: Shutterstock

Investors were underwhelmed by the solid earnings posted by AnaptysBio, Inc. (NASDAQ:ANAB) recently. We did some digging and actually think they are being unnecessarily pessimistic.

View our latest analysis for AnaptysBio

earnings-and-revenue-history
NasdaqGS:ANAB Earnings and Revenue History November 11th 2021

A Closer Look At AnaptysBio's Earnings

In high finance, the key ratio used to measure how well a company converts reported profits into free cash flow (FCF) is the accrual ratio (from cashflow). The accrual ratio subtracts the FCF from the profit for a given period, and divides the result by the average operating assets of the company over that time. The ratio shows us how much a company's profit exceeds its FCF.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

For the year to September 2021, AnaptysBio had an accrual ratio of -0.44. That indicates that its free cash flow quite significantly exceeded its statutory profit. To wit, it produced free cash flow of US$15m during the period, dwarfing its reported profit of US$8.39m. Given that AnaptysBio had negative free cash flow in the prior corresponding period, the trailing twelve month resul of US$15m would seem to be a step in the right direction.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On AnaptysBio's Profit Performance

Happily for shareholders, AnaptysBio produced plenty of free cash flow to back up its statutory profit numbers. Because of this, we think AnaptysBio's underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! And one can definitely find a positive in the fact that it made a profit this year, despite losing money last year. Of course, we've only just scratched the surface when it comes to analysing its earnings; one could also consider margins, forecast growth, and return on investment, among other factors. If you'd like to know more about AnaptysBio as a business, it's important to be aware of any risks it's facing. For example, we've found that AnaptysBio has 2 warning signs (1 can't be ignored!) that deserve your attention before going any further with your analysis.

This note has only looked at a single factor that sheds light on the nature of AnaptysBio's profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying.

Discounted cash flow calculation for every stock

Simply Wall St does a detailed discounted cash flow calculation every 6 hours for every stock on the market, so if you want to find the intrinsic value of any company just search here. It’s FREE.

Make Confident Investment Decisions

Simply Wall St's Editorial Team provides unbiased, factual reporting on global stocks using in-depth fundamental analysis.
Find out more about our editorial guidelines and team.